Introduction: The protein protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clinical practice. However, only a small percentage of cancer patients benefit from PD1/PD-L1 directed mAbs. Moreover, some patients experience immune related side effects upon treatment with these mAbs. Recently, several atomic-resolution structures of human PD1/PD-L1, and small molecules, peptides and mAbs with PD-L1 and PD1 open the field for structure based drug design. Small molecules and peptides targeting PD1/PD-L1 promise to enhance tumor activity while showing less immune related side effects. Areas covered: We reviewed the small molecules classes and peptides targeting PD1/PD-L1. Expert opinion: Currently approved PD1/PD-L1 directed therapeutics show room for improvement. Three classes of non mAb small molecule classes have been discovered so far: (cyclic) peptides as direct competitive PD1/PD-L1 antagonists; small molecules disrupting PD1/PD-L1 and inducing a PD-L1 dimerization; and a small molecule class of unknown mode-of-action. An example of the later group CA-170 is currently investigated in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Potential advantages of small molecules over mAbs include high distribution and better tumor penetration, improved PK/PD, less side effects and oral bioavailability.
M a n u s c r i p t 
1.

Targetin
Small Molecules
Researchers at Bristol-Myers Squibb (BMS) company discovered multiple small molecules for the inhibition of the PD-1/PD-L1 axis. These compounds are useful in cancers that suppress the immune system and in metastases that express the PD-L1 ligand. The described molecules can also be potentially used in combination with regular anti-cancer therapies such as radiotherapy, standard immunotherapy and chemotherapy. They can also be useful in HIV, infectious diseases and in hepatitis.
The general structure 1 for one series of these compounds is shown in scheme 1. 2 For the determination of the ability of these compounds to bind to PD-L1, PD-1/PD-L1 homogenous timeresolved fluorescence (HTRF) binding assay was used and the measured IC 50 values were in the range of 0.006 µM to 10 µM for 297 described compounds (scheme 1). BMS chemists also disclosed 1,3-dihydroxy phenyl derivatives with general structure 2 that inhibit PD-1/PD-L1 PPI with IC 50 values in the range of 0.60 nM to 20 µM. However, no in vivo characterization of these small molecules have been performed in this trial (scheme 1). 3 The first co-crystal structures of hPD-L1 complexed with small molecular weight inhibitors (examples 1 and 2, scheme 1) disclosed in the BMS patent were reported previously. 4 More recently, structural studies revealed that examples 3 and 4 induce conformational changes in the PD-L1 binding site, upon the complex formation (scheme 1). Thus, it presents several opportunities for the design of more potent inhibitors of PD-1/PD-L1 interaction. 5, 6 Another class of 1,3-dihydroxy phenyl derivatives with general structure 3 was disclosed by BMS as immunomodulators which are useful for the treatment of various disorders, including cancer and infectious diseases. The binding properties (IC 50 ) of these compounds to PD-1/PD-L1 were determined using HTRF binding assay. 7 BMS researchers reported more potent PD-1/PD-L1 inhibitors (IC 50 0.21 nM-10 µM) with general structure 4 that include the extended sidechains of the phenyl group. 8 Some representative examples with IC 50 values of less than 1 nM are shown in scheme 1. BMS researchers in their recently published patent reported biaryl compounds with general structure 5 as inhibitors of PD-1/PD-L1 and CD80/PD-L1 PPIs. 9 The compounds with a (pseudo)symmetric structure (examples 9, 10) are characterized with the lowest IC 50 values. M a n u s c r i p t Arising International LLC researchers recently disclosed (pseudo)symmetric compounds with general structure 6 as inhibitors of PD-1/PD-L1 and CD80/PD-L1 PPIs (scheme 2). Based on docking experiments, example 11 was selected as ligand binding to the PD-L1 dimer (pdb code of PD-L1 dimer: 5J8O). As shown in the patent, the hydrophobic channel accommodates the core scaffold in the center and two (pseudo)symmetrical side chains attached to the core are extended to either side of the dimer interface. It is believed that these inhibitors can effectively induce/stabilize PD-L1 dimer formation, therefore potently disrupting PD-1/PD-L1 and CD80/PD-L1 PPIs. To assess the antagonist activity of the compounds, HTRF binding assay using extracellular domains of PD-1 and PD-L1 M a n u s c r i p t Chemists from the company Polaris Pharmaceuticals Inc. have also described biaryl derivatives binding to the PD-1/PD-L1 and CD80/PD-L1 axes (scheme 3). The disclosed general structure 7 consists of a tetra-aromatic ring system, similar to the BMS compounds superimposed within distal phenyl ring of biphenyl moiety. All of these compounds are symmetrical biphenyls and their ability to block PD-1/PD-L1 interaction was established based on enzyme-linked immunosorbent assay (ELISA). Replacing the Br groups by acetylene moieties on the phenyl group in this class of compounds caused a significant reduction in the IC 50 value (examples 13, 14, scheme 3).
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Scheme 3. The general structure and examples of the compounds patented by Polaris Pharmaceuticals Inc.
Chemocentryx Inc. researchers published immunomodulatory compounds with general structure 8 as shown in scheme 4. These compounds were evaluated as inhibitors of the PD-1 pathway by biochemical interaction assay based on ELISA platform by human PD-L1. IC 50 values of the most potent compounds are less than 100 nM (examples 15, 16).
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A c c e p t e d M a n u s c r i p t The Institute of Materia Medica (Chinese Academy of Medical Sciences) has filed patents for bromobenzyl ether derivatives of general structures 9
13
, 10 14 and 11 15 . Core structure includes a tetra substituted 1,3-dioxophenyl with an appendant bromobenzyl ether. The disclosed compounds are potential therapeutics for treating diseases related to PD-1/PD-L1 signal channels such as cancers, infectious diseases and autoimmune disorders. The biological activity as inhibitors of PD-1/PD-L1 axis was determined by HTRF PD-1/PD-L1 Binding Assay (Cisbio). The strong binding affinity of the compounds to PD-L1 was evaluated using Biacore. Guangzhou Maxinovel Pharmaceuticals Co., Ltd. disclosed aromatic acetylene or aromatic ethylene derivatives as PD-1/PD-L1 inhibitors. 16 The bioactivity of the compounds was assessed by HTRF using Cisbio PD-1/PD-L1 binding assay kit. Out of 69 compounds reported in the patent, 3 are acetylene derivatives. Changing the acetylene moiety in example 24 to an ethylene moiety, example 23, the IC 50 value has decreased from 1.34 M to 18 nM (scheme 6). Recently, Maxinovel Pharmaceuticals A c c e p t e d M a n u s c r i p t described orally active PD-1/PD-L1 antagonists efficacy of single agent or combination in mouse models.
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Scheme 6. The general structure and examples of the compounds patented by Guangzhou Maxinovel Pharmaceuticals Co., Ltd.
Researchers from Aurigene Discovery Technologies Limited in Bangalore, India, discovered oxadiazole and thiadiazole structures which are inhibitors of the PD-1/PD-L1 interaction.
General structures (13 18 , 14 19 and 15
20
) of 1,3,4-oxadiazoles and 1,3,4-thiadiazoles are shown in scheme 7. The inhibition activity of these compounds was measured by percent rescue of mouse splenocyte proliferation in the presence of recombinant mouse PD-L1 (general structure 13 and 14) and recombinant mouse PD-L1/PD-L2 (general structure 15) at 100 nM compound concentration. Example 30 shows 92% splenocyte proliferation at 100 nM compound concentration which is the highest among 1,3,4-oxadiazoles and 1,3,4-thiadiazoles reported by this group. 20 Oxadiazoles compared to thiadiazoles show better activity and the most active compounds in this class contain primary amine and urea moieties. Scientists from Aurigene Ltd. have also claimed 1,2,4-oxadiazoles and 1,2,4-thiadiazoles with general structures 16 21 , 17 22 and 18 23 as inhibitors of PD-1/PD-L1 pathway (scheme 8). The inhibition activities of the compounds were assessed by rescue of mouse splenocyte proliferation in the presence of recombinant mouse PD-L1/PD-L2 (general structure 16) and recombinant mouse PD-L1 Recently, researchers from Aurigene Ltd. disclosed cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds of general structure 19 24 and substituted-1,2,4-oxadiazole compounds of general structure 20. 25 Similarly to previous disclosures, any example with thiadiazole core is not directly presented in the patent. The compounds are claimed to enhance the immune response, therefore can be used for the treatment of disorders, comprising aberrations of the PD-1 pathway. Among the reported compounds in these patents, example 37 have highest percent rescue of mouse splenocyte proliferation in the presence of recombinant PD-L1/PD-L2 at 100 nM concentration of the compound. However, it should be noted that mouse and human PD-L1 differ in amino acid sequence. M a n u s c r i p t Incyte Corporation filed patents for 5 series of compounds with general structures 21 26 , 22 27 , 27 28 , 28 29 , 29 30 , 24 31 , 25 32 , 26 33 and 23 34 as shown in scheme 10. These compounds modulate PD-1/PD-L1 PPI and are useful in treating, preventing or ameliorating diseases and disorders such as cancer or infections. PD-1/PD-L1 HTRF binding assay with recombinant human PD-L1 protein was used to validate the activity of these compounds.
A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t
Dömling from the University of Groningen in the Netherlands filed a patent with 60 examples of the general structure 30 as inhibitors of the PD-1/PD-L1 PPI (scheme 11). The binding affinity of these compounds was analyzed by differential scanning fluorimetry (DSF) and NMR using recombinant human PD-1 and PD-L1 proteins and all of them showed activity (IC 50 ) in the range of 0.001-1000 µM.
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Scheme 11. The general structure and examples of the compounds patented by University of Groningen.
Peptides
Several peptides and peptidomimetic compounds that inhibit the PD-1/PD-L1 pathway were discovered. In 2014, researchers from Aurigene Ltd. have reported compounds with the general structure 31 (scheme 12). The activity of these compounds was determined by carboxyfluorescein diacetate succinimidyl ester (CFSE) proliferation assay. CFSE is a dye that passively diffuses into cells and binds to intracellular proteins. One of the most promising compounds of this group is example 61 which was found to have a 4-fold induction of the splenocyte proliferation at 100 nM concentration as compared to the background (the proliferation of splenocytes while exposed to PD-L or a tumor). Interestingly, this compound was also subjected to in vivo activity test-on metastasis of B16F10 melanoma in female mice. The 64% reduction of the metastasis was observed at 5 mg/kg dose of the compound. 36 Researchers from Aurigene Ltd. have also described potent peptides with general structure 32 (scheme 12). Most active compounds in this class contain 1,2-disubstituted hydrazine and urea moieties. The best example 63 induces a recovery of the splenocyte proliferation of 87% at a compound concentration of 100 nM. A c c e p t e d M a n u s c r i p t
Macrocycles
Several PD-1/PD-L1 inhibitors based on macrocyclic peptide structures were reported. These molecules have been proven to be effective antagonists for this PPI by biochemical and cell-based experiments.
The blockage of the PD-1/PD-L1 PPI by these macrocycles results in enhanced T-cell response and thus improving the immune system. The modulation of this PPI is relevant for the improvement of cancer therapy, HIV therapy, chronic viral infections and numerous other immunological diseases.
Over the last couple of years, researchers from BMS company have reported a vast number of macrocyclic compounds that show activity in inhibiting the PD-1/PD-L1 pathway. Macrocycles with general structure 33 38, 39 disclosed by BMS company are claimed to inhibit PD-1/PD-L1 and PD-L1/CD80 PPIs (scheme 13). The macrocycle core contains in all cases a thioether bond. The ability of these macrocycles to bind to PD-L1 was investigated using a PD-1/PD-L1 HTRF binding assay and the IC 50 values of examples 65, 66 and 67 were established (scheme 13). 38 The ability of these macrocycles to promote IFNγ secretion was assessed by the cytomegalovirus (CMV) -specific T-cell function assay. The response of for example 66 is EC 50 of 300 nM. These results show that PD-L1 binding with these macrocycles inhibitors can enhance IFNγ release in a memory T-cell population generated from previous exposure to a persistent antigen. The ability of these macrocycles to bind to PD-L1 was tested in cell binding assays using Jurkat mouse B and a human lung adenocarcinoma cell lines. Cell binding hPD-L1/PD-1 IC 50 for examples 66 and 67 are 10 nM and 1400 nM, respectively. Recently, in-depth characterization of three macrocyclic peptide inhibitors disclosed by BMS researchers were published (examples 65, 66 and 67). It was shown that these macrocyclic compounds directly bind to PD-L1, antagonize this protein signalling and similar to antibodies can restore the function of T-cells. Moreover, the co-crystal structures of examples 65 and 66 in the complex with PD-L1 protein were proven recently.
